November 3, 2025 — Leads & Copy — Exact Sciences Corp. (Nasdaq: EXAS) reported revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024.
Screening revenue increased 22% to $666 million, while Precision Oncology revenue rose 13% to $184 million. Net loss improved to $20 million, or $0.10 per share. Adjusted EBITDA increased 37% to $135 million, with a 16% margin. The company updated its full-year 2025 revenue guidance to $3.220 – $3.235 billion and adjusted EBITDA guidance to $470 – $480 million.
Exact Sciences launched its Cancerguard® multi-cancer early detection (MCED) test as a laboratory-developed test in September 2025. It also announced an agreement with Quest Diagnostics to enable blood collection for Cancerguard at Quest’s patient access sites across the U.S.
Company management will host a conference call and webcast on Monday, November 3, 2025, at 5 p.m. ET to discuss third-quarter 2025 results.
Contact: Investor Relations, ir@exactsciences.com
Source: Exact Sciences Corp.
